

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/700,274	11/03/2003	Joseph S. Podolski	07189.0014.DVUS02	9175
7590 10/26/2004			EXAMINER	
IP Prosecution			WEBMAN, EDWARD J	
HOWREY SIMON ARNOLD & WHITE, LLP Box No. 34			ART UNIT	PAPER NUMBER
1299 Pennsylvania Avenue, N.W.			1617	
Washington, DC 20004-2402			DATE MAILED: 10/26/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

2	
ODOLSK)	
Group Art Unit	
1617	
rrespondence address	
FROM THE MAILING DATE	
timely filed after SIX (6) MONTHS days will be considered timely. e of this communication . NED (35 U.S.C. § 133).	
7 * * *	
•	
the merits is closed in	
pending in the application.	
vithdrawn from consideration.	
allowed.	
ejected. objected to.	
bjected to.	
oject to restriction or election ment.	
4	
i.	
· · · · · · · · · · · · · · · · · · ·	
······································	
·	
nary, PTO-413	
☐ Notice of Informal Patent Application, PTO-152	
ĭ	

U. S. Patent and Trademark Office PTO-326 (Rev. 9-97)

Part of Paper No. LO/LO4

Application/Control Number: 10/700,274

Art Unit: 1617

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 19, 20, 22, 28-36 are rejected under 35 U.S.C. 103(a) as being unpatentable over Virag.

Virag teaches a composition for treatment of impotence (Title) comprising papavaizing, lengthual phentolamine and 33 ug of alprostadil (column 2, lines 64-68).

It would have been obvious to one of ordinary skill to administer a composition domprising papaverine, phentolamine and alprostabil for the beneficial effect of treating impotence in view of Virag.

As to the claimed buffer, the examiner takes judicial notice under MPEP 2144.03 that the optimal pH for papaverine solutions is 2-2.8. Thus, it would be an obvious expedient to buffer the Virag composition near pH 3. As to the claimed ratios and amounts, selecting optimum ranges are within the skill of the art In re Boesch 205 USPQ 215 (CCPA 1980), absent evidence showing such ratios and amounts are critical.

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

Application/Control Number: 10/700,274

Art Unit: 1617

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 19, 20, 22-36 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 18-37 of U.S.

Patent No. 6482426. Although the conflicting claims are not identical, they are not patentably distinct from each other because

the instant claims encompass the scope of the buffer in the patented elaims.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Edward Webman whose telephone number is (571) 272-0633. The examiner can normally be reached on Monday to Friday 9 Am 5 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, S. Padmanabhan can be reached on (571) 272-0629. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

EDWARD JWEBNAN PRIMARY EXAMINER GROUP 1500